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showed a decreasing tendency following the introduction of
organized screening programme.
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OBJECTIVE: The cost of illness due to cancer is substantial in
terms of both human suffering and economic resources. The
growth in cancer treatment spending in the United States is due in
large part to increases in survival and cancer prevalence. The
objective of this study is to analyze the growth in spending on
direct medical costs for cancer treatment using a prevalence-based
cost-of-illness approach. Direct costs include personal health care
expenditures for hospital and nursing home care, physician and
other professional services, drugs, and home care. METHODS:
Estimates for cancer prevalence counts in the year 2004 were
derived by applying U.S. Census population data to National
Cancer Institute Surveillance Epidemiology and End Results
(SEER 9) and historical Connecticut Limited Duration Prevalence
proportions. Cancer treatment cost estimates were based on
Centers for Medicare & Medicaid Services projections for total
2005 health expenditures by type of direct costs, and the National
Center for Health Statistic’s methodology for calculating direct
costs for major diagnostic groups. Cancer treatment spending and
national health care expenditure values were adjusted to year
2005 dollars using the Consumer Price Index—All Urban Con-
sumers. RESULTS: From 1985 to 2004, inﬂation adjusted per-
capita national health care expenditures increased 70%, while
inﬂation adjusted cancer treatment spending per prevalent case
increased 16%. In 2004, cancer spending per prevalent case
($6862) was on par with per-capita total health care spending
($6492). CONCLUSION: Per-capita health care spending has
increased signiﬁcantly over the past two decades in comparison to
cancer spending per prevalent case. Prevalence-based costing
acknowledges that the direct costs of cancer care in any given year
are attributable to new and previously diagnosed cancer patients.
Our analysis underscores the importance of evaluating spending
on cancer care in the context of overall health care spending,
cancer survival rates, and disease prevalence.
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OBJECTIVE: Cancer continues to be a leading cause of death,
but the last few decades have seen many changes in the diagnosis
and treatment of the disease. In this study, we estimate the
economic value of gains in cancer survival over the last 20 years,
separate these gains into the portions due to improvements in
treatment and detection, and determine the extent to which the
economic value of gains in cancer survival have been divided
between patients and ﬁrms. METHODS: Using methodology
developed by Philipson and Jena (2005), we estimated the eco-
nomic value of gains in cancer survival between 1990 and 2000.
We then used estimates from the literature to calculate expendi-
tures on cancer treatment, thereby allowing us to determine how
the social value of gains in cancer treatment has been divided
between patients and ﬁrms. RESULTS: The value of survival
gains for all cancers combined was worth roughly $28,000–
$30,000 per cancer patient, and most (78–88%) of this gain has
been driven by improvements in treatment. For all cancers com-
bined, improvements in cancer survival between 1990 and 2000
had a social value of roughly $1.6–$1.9 trillion, and health care
providers were able to appropriate 6–19% of this total, with the
rest accruing to patients. CONCLUSION: The social value of
recent gains in cancer survival is very large. Most of this gain has
been driven by improvements in cancer treatment, and has been
appropriated by patients, not health care providers.
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OBJECTIVE: To describe how decision making in the Cancer
Subcommittee of the Ontario Committee to Evaluate Drugs
(responsible for deciding which novel and costly cancer drugs
will be funded in Ontario) is evolving along three scientiﬁc para-
digms. METHODS: We describe how these paradigms shape
both criteria and process of decision making. We also systemati-
cally reviewed meeting transcripts to analyze decisions made in
2006. RESULTS: Evidence Based Medicine (I) is part of decision
making through rigorous evidence reviews and the implicit rule
that drugs must pass the threshold of effectiveness to be funded.
Although drugs must pass one evidence threshold to be licenced
in Canada, higher standards are required for reimbursement (e.g.
phase III controlled trial data, peer reviewed publication). Health
economic criteria (II) are assuming greater weight in decision
making, as the review process is standardized, committee
members become more economically literate, and a cancer phar-
macoeconomics unit is established. The process of decision
making (versus decision criteria) is evolving using the ethical
foundations of Accountability for Reasonableness (III), impor-
tant tenets of which are transparency, accountability, and stake-
holder involvement in the decision process. Review of the 2006
decisions showed that 16 of 37 drugs were funded (43%).
Among negative funding decisions 86% were characterized by
inadequate evidence (main reason in 43%), 71% were charac-
terized by cost effectiveness concerns (main reason in 15% ), and
5% by ethical concerns (main reason in 5%). Forty-eight percent
of decisions were multifactorial. CONCLUSION: Each para-
digm used to make cancer drug funding decisions comes from a
distinct intellectual tradition. Most decisions in 2006 were based
on more than one paradigm. We believe that optimal decision
making for cancer drugs involves integrating concepts from all
traditions, involving both distinct decision criteria and decision
processes. Integration requires judicious tradeoffs between both
efﬁciency and equity, and evidence quality and efﬁciency/equity.
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OBJECTIVE: Evaluate predictors of four major therapeutic
choices (surgery, radiation, chemotherapy, immunotherapy) in
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